RAFFA WEALTH MANAGEMENT, LLC’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$242 Hold
16
﹤0.01% 1241
2026
Q1
$174 Hold
16
﹤0.01% 1200
2025
Q4
$207 Hold
16
﹤0.01% 1131
2025
Q3
$207 Hold
16
﹤0.01% 1145
2025
Q2
$285 Hold
16
﹤0.01% 1053
2025
Q1
$285 Hold
16
﹤0.01% 1023
2024
Q4
$477 Hold
16
﹤0.01% 1009
2024
Q3
$250 Hold
16
﹤0.01% 1045
2024
Q2
$274 Hold
16
﹤0.01% 1107
2024
Q1
$250 Hold
16
﹤0.01% 1092
2023
Q4
$239 Hold
16
﹤0.01% 1027
2023
Q3
$258 Hold
16
﹤0.01% 1012
2023
Q2
$664 Hold
16
﹤0.01% 907
2023
Q1
$962 Hold
16
﹤0.01% 803
2022
Q4
$1.17K Hold
16
﹤0.01% 732
2022
Q3
$1.22K Hold
16
﹤0.01% 734
2022
Q2
$1.11K Hold
16
﹤0.01% 781
2022
Q1
$1.33K Hold
16
﹤0.01% 760
2021
Q4
$1.2K Sell
16
-4
-20% -$402 ﹤0.01% 811
2021
Q3
$2.32K Hold
20
﹤0.01% 577
2021
Q2
$4.44K Hold
20
﹤0.01% 408
2021
Q1
$2.64K Buy
20
+16
+400% +$2.53K ﹤0.01% 561
2020
Q4
$692 Buy
+4
New +$547 ﹤0.01% 813
2020
Q2
Sell
-6
Closed -$404 895
2020
Q1
$404 Buy
+6
New +$474 ﹤0.01% 781

Other funds holding NVCR

RAFFA WEALTH MANAGEMENT, LLC's NVCR Position: Q2 2026 in Review

RAFFA WEALTH MANAGEMENT, LLC held its NovoCure (NVCR) position steady in Q2 2026 at 16 shares worth $242. The position accounts for ﹤0.01% of the portfolio, ranked #1241.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in NVCR in Q1 2020 and has held it in 24 quarters since. The position peaked at $4.44K in Q2 2021. 37 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • RAFFA WEALTH MANAGEMENT, LLC held 16 shares of NovoCure worth $242 as of Q2 2026.
  • RAFFA WEALTH MANAGEMENT, LLC left its NovoCure share count unchanged in Q2 2026.
  • NovoCure made up ﹤0.01% of RAFFA WEALTH MANAGEMENT, LLC's portfolio in Q2 2026, its #1241 holding.
  • RAFFA WEALTH MANAGEMENT, LLC first reported a position in NovoCure in Q1 2020 and has held it in 24 quarters since.
  • RAFFA WEALTH MANAGEMENT, LLC's NovoCure position peaked at $4.44K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2026, filed 27 Jul 2026.